3D Medicines Bleeds Red Ink As It Struggles to Swim in ‘Red Ocean’
The loss-making innovative oncology drug company with just one approved product on the market is making a third tilt for a listing on the Hong Kong Stock Exchange Key Takeaways:…
RELATED ARTICLES
-
Profit setback for Simcere Pharma in novel drugs quest
2096.HK
-
Clinical trials come up short again for Alphamab Oncology
9966.HK
- Increasing losses prompt Zephyrm Bioscience to seek funds through IPO
-
Tian Tu plunges into the red on sagging Hong Kong stock market
1973.HK
- CHINA BULLETIN: Services, Trade Send Positive Signals
-
Shunned by investors, Henlius hangs up on its Hong Kong listing
2696.HK
Discover hidden China stock gems in our weekly newsletter